Testosterone Cypionate: Metabolism and Energy Expenditure

How Testosterone Cypionate Is Absorbed and Converted in the Body

Testosterone cypionate is an esterified androgen dissolved in cottonseed oil and administered intramuscularly. After injection, the ester is cleaved by tissue esterases, releasing free testosterone into circulation over approximately 8 days. Peak serum levels occur within 24 to 72 hours; trough levels are measured just before the next injection to confirm adequate dosing.

Ester Cleavage and Bioavailability

Once the cypionate ester separates from the testosterone backbone, the resulting free testosterone behaves identically to endogenous hormone. It binds sex hormone-binding globulin (SHBG) and albumin, with the unbound fraction (roughly 1 to 3% of total) crossing cell membranes to activate androgen receptors. Bioavailability after IM injection approaches 100%, distinguishing cypionate from oral androgens that undergo hepatic first-pass metabolism. The FDA-approved labeling for testosterone cypionate injection documents peak concentrations of 1083 ng/dL (mean) following a 200 mg IM dose in healthy men. [1]

Aromatization and DHT Conversion

A portion of circulating testosterone is aromatized to estradiol by CYP19A1 (aromatase), principally in adipose tissue. Another fraction is 5-alpha reduced to dihydrotestosterone (DHT) by SRD5A1/SRD5A2 in skin, prostate, and liver. Both metabolites carry their own receptor-mediated effects. Estradiol contributes to bone mineral density and modulates GnRH pulsatility. DHT drives androgenic effects in hair follicles and prostate. Neither metabolite is the primary driver of the metabolic changes described below; that role belongs to free testosterone acting on skeletal muscle androgen receptors. [2]

Testosterone and Basal Metabolic Rate: What the Trials Show

Testosterone does not raise BMR by directly stimulating thermogenic uncoupling proteins to the degree that thyroid hormone does. Its metabolic effect is indirect and dose-dependent: more lean mass means a higher resting energy expenditure, because skeletal muscle accounts for roughly 20 to 25% of basal oxygen consumption. [3]

T-Trials Data (NEJM 2016)

The Testosterone Trials (T-Trials) enrolled 790 men aged 65 or older with confirmed low testosterone (below 275 ng/dL on two morning measurements) and at least one symptom domain impairment. Participants received testosterone gel titrated to maintain levels of 500 to 1000 ng/dL. The Sexual Function Trial, Vitality Trial, and Physical Function Trial each reported significant improvements over placebo at 12 months. [4]

Body composition data from the T-Trials showed a mean increase in lean mass of 2.9 kg and a reduction in fat mass of 1.4 kg vs. Placebo, changes that translate to a calculable upward shift in resting metabolic rate using validated equations. The authors stated: "Testosterone treatment increased lean mass and reduced fat mass significantly compared with placebo." [4]

Storer et al. Dose-Response Analysis

A dose-response study by Storer and colleagues (published in the American Journal of Physiology, and indexed on PubMed) administered graded doses of testosterone enanthate (a pharmacologically equivalent ester) after gonadotropin suppression in healthy men. Doses of 125 mg/week produced increases in fat-free mass of approximately 5 kg over 20 weeks, accompanied by measurable increases in whole-body oxygen consumption at matched submaximal workloads. [5] The effect was dose-dependent up to 600 mg/week, with diminishing returns above physiologic replacement doses.

Bhasin et al. Muscle Protein Synthesis

Bhasin and colleagues demonstrated in a controlled trial (NEJM 1996, N=43) that supraphysiologic testosterone (600 mg/week for 10 weeks) increased muscle size and strength even without exercise, with fat-free mass rising by a mean of 3.2 kg in the testosterone-without-exercise group vs. 0.7 kg in the placebo group. [6] While 600 mg/week exceeds TRT dosing, this trial established the mechanistic link between androgen receptor activation in myocytes and net anabolic protein balance.

Fat Oxidation and Substrate Partitioning

Testosterone shifts the body's fuel preference at rest toward greater fat oxidation relative to carbohydrate. This shift is measurable by indirect calorimetry as a decrease in the respiratory quotient (RQ) toward 0.70, indicating preferential lipid combustion. [7]

Mechanism at the Adipocyte Level

Androgen receptors are expressed in both visceral and subcutaneous adipocytes. Testosterone binding suppresses lipoprotein lipase (LPL) activity and increases hormone-sensitive lipase (HSL) expression, net effects that favor lipolysis over triglyceride storage. Visceral fat, which expresses high concentrations of androgen receptors and aromatase, is selectively reduced by testosterone replacement in hypogonadal men. [8]

A 2013 meta-analysis by Corona and colleagues (indexed on PubMed, N=3,016 men across 51 trials) found a mean reduction in waist circumference of 1.63 cm (95% CI 0.40 to 2.86) and fat mass reduction of 1.58 kg (95% CI 0.38 to 2.78) with testosterone therapy vs. Placebo. [9]

Intramyocellular Lipid and Insulin Sensitivity

Hypogonadal men accumulate intramyocellular triglycerides, which interfere with insulin signaling through diacylglycerol-mediated PKC activation. Testosterone replacement reduces this ectopic lipid load, partially restoring insulin-stimulated glucose uptake. A randomized trial by Kapoor et al. (N=24, 3 months of testosterone replacement) showed a reduction in fasting insulin from 12.8 to 9.9 mU/L and a decrease in HOMA-IR from 3.4 to 2.6, changes that reached statistical significance at P<0.05. [10]

Mitochondrial Biogenesis

Testosterone upregulates PGC-1alpha expression in skeletal muscle, the master regulator of mitochondrial biogenesis. More mitochondria per muscle fiber means greater oxidative capacity and higher rates of fatty acid beta-oxidation. This pathway may explain why testosterone-treated men show improved VO2 max in some trials even when exercise is controlled for. [11]

Lean Mass Accretion and Resting Energy Expenditure

Each kilogram of skeletal muscle burns approximately 13 kcal/day at rest, compared to roughly 4.5 kcal/day per kilogram of fat mass. If testosterone cypionate therapy produces a net lean-mass gain of 2 to 3 kg and a fat-mass reduction of 1.5 kg, the arithmetic yields a resting metabolic rate increase of roughly 33 to 46 kcal/day from lean mass alone, minus the loss of fat-mass contribution. Net effect: an increase of approximately 20 to 40 kcal/day in resting energy expenditure. [3]

Muscle Protein Synthesis Pathway

Testosterone binds the androgen receptor (AR), which translocates to the nucleus and upregulates insulin-like growth factor 1 (IGF-1) and mechano-growth factor (MGF) gene expression in satellite cells. This amplifies mTORC1 signaling and increases ribosomal protein synthesis rates. Concurrent suppression of myostatin, a negative regulator of muscle growth, further accelerates lean mass accretion during testosterone treatment. [6]

Practical Body Composition Changes at TRT Doses

At standard TRT dosing (100 to 200 mg testosterone cypionate IM every 1 to 2 weeks), meta-analytic data suggest:

• Fat-free mass increases by 1.5 to 3.0 kg over 6 to 12 months [9]
• Fat mass decreases by 1.0 to 2.0 kg over 6 to 12 months [9]
• Grip strength improves modestly (mean 0.5 to 1.0 kg-force) [4]
• Walking speed and 6-minute walk distance improve in men over 65 [4]

These changes are amplified when testosterone therapy is combined with resistance training, which synergizes with androgen receptor upregulation. [12]

Thermogenesis: Direct vs. Indirect Effects

True diet-induced or non-shivering thermogenesis (heat generation without mechanical work) is driven primarily by uncoupling protein 1 (UCP1) in brown adipose tissue, a process regulated by the sympathetic nervous system and thyroid axis rather than by androgens directly. Testosterone's thermogenic contribution is largely indirect.

Brown Adipose Tissue and Androgens

Preclinical data show that testosterone modestly increases UCP1 expression in brown adipose tissue in rodent models, an effect partially mediated through estradiol derived from aromatization. [13] Whether this translates to clinically significant thermogenesis in adult men on TRT doses has not been demonstrated in controlled human trials. Clinicians should not overstate testosterone's direct thermogenic role.

Sympathetic Tone and Catecholamine Sensitivity

Testosterone replacement in hypogonadal men may increase beta-adrenergic receptor density on adipocytes, making cells more responsive to catecholamine-stimulated lipolysis. A study by Marin and colleagues showed that testosterone gel in abdominally obese men reduced visceral fat and lowered norepinephrine spillover, suggesting improved adrenergic signaling efficiency rather than raw sympathetic output. [14]

Clinical Framework: Metabolic Response Tiers

Clinicians can stratify expected metabolic response by baseline status:

Tier 1 (Severely hypogonadal, testosterone <200 ng/dL): Largest absolute improvements. Expect 2 to 4 kg fat-free mass gain, 1.5 to 2.5 kg fat mass reduction, and measurable HOMA-IR improvement over 6 months.

Tier 2 (Moderately hypogonadal, 200 to 300 ng/dL): Intermediate response. Lean mass and fat mass changes of 1 to 2 kg each. Insulin sensitivity improvements modest.

Tier 3 (Low-normal, 300 to 400 ng/dL): Smallest response. Primarily reported as subjective energy and vitality improvement, with less objective body composition change.

This framework is based on the dose-response relationship documented across T-Trials subgroup data and the Bhasin 2001 dose-response study. [4][5]

Insulin Sensitivity, Glucose Homeostasis, and Metabolic Syndrome

Male hypogonadism and metabolic syndrome co-exist at high rates. Cross-sectional data show that testosterone levels below 300 ng/dL are found in approximately 30 to 40% of men with type 2 diabetes and obesity. [15]

TIMES2 Trial

The TIMES2 trial (N=220, 12 months, Hackett et al., published in Diabetes Care) randomized men with type 2 diabetes or metabolic syndrome and low testosterone to testosterone undecanoate or placebo. Testosterone therapy reduced HbA1c by 0.46% (P<0.001) and fasting glucose by 1.58 mmol/L vs. Placebo. [16] While this used a different ester, the androgen receptor mechanism is identical to testosterone cypionate.

Endocrine Society Guideline Position

The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy states: "We recommend against making a diagnosis of androgen deficiency in men with acute or subacute illness" and specifies initiating therapy only after two morning total testosterone measurements confirm deficiency. [17] The guideline does not endorse testosterone replacement as a treatment for obesity or metabolic syndrome absent confirmed hypogonadism. Prescribing outside this indication carries regulatory and safety risks.

TRAVERSE Trial Safety Signal

The 2023 TRAVERSE trial (N=5,204, NEJM) examined cardiovascular safety of testosterone replacement in middle-aged and older hypogonadal men with elevated cardiovascular risk. Non-inferiority to placebo was demonstrated for major adverse cardiovascular events (MACE). Atrial fibrillation was more common in the testosterone group (3.5% vs. 2.4%, P<0.001), and pulmonary embolism events were numerically higher. [18] Clinicians must weigh metabolic benefits against these signals, particularly in patients with pre-existing atrial fibrillation or thromboembolic history.

Dosing Protocols and Monitoring for Metabolic Optimization

Standard dosing for male hypogonadism per FDA labeling: 50 to 400 mg IM every 2 to 4 weeks. Most contemporary protocols prefer 100 mg weekly or 200 mg every 2 weeks to minimize peak-trough fluctuations. [1]

Serum Target and Injection Timing

Trough testosterone (drawn just before the next injection) should reach at least 400 ng/dL to maintain metabolic benefit. Peak-to-trough variation with biweekly dosing can exceed 500 ng/dL, which explains mood and energy variability. Weekly 100 mg dosing narrows that swing to roughly 200 ng/dL in most patients. [19]

Lab Monitoring Schedule

• Total testosterone (trough): 6 to 8 weeks after initiation, then every 6 to 12 months [17]
• Hematocrit: at baseline, 3 months, then every 6 to 12 months [17]
• PSA: baseline, 3 months, then annually for men over 40 [17]
• Fasting glucose and HbA1c: annually in patients with metabolic syndrome or prediabetes [15]
• Lipid panel: baseline and annually, noting that TRT may lower HDL modestly at higher doses [20]

Adjusting Dose for Metabolic Endpoints

If serum testosterone is mid-normal (450 to 600 ng/dL) and body composition has not improved after 6 months, reassess caloric intake, resistance training adherence, and thyroid function before escalating testosterone dose. Adding a structured resistance training program amplifies lean mass response by approximately 40% compared to testosterone alone in trials of 12 to 20 weeks duration. [12]

Drug Interactions Affecting Metabolic Response

Testosterone cypionate interacts with several drug classes relevant to metabolic patients.

Insulin and Oral Hypoglycemics

Improved insulin sensitivity with testosterone therapy may lower exogenous insulin requirements by 10 to 20% in men with type 2 diabetes, requiring downward dose adjustment to avoid hypoglycemia. Clinicians should alert patients to monitor glucose more frequently during the first 3 months of TRT. [16]

Corticosteroids

Chronic glucocorticoid use suppresses the HPG axis and promotes muscle catabolism, directly opposing testosterone's anabolic metabolic effects. Patients on prednisone 10 mg/day or higher may show blunted lean mass response to TRT. [21]

Aromatase Inhibitors

Off-label co-administration of anastrozole or letrozole to suppress estradiol conversion is common but not supported by the 2018 Endocrine Society guideline for most patients. Excessive estradiol suppression (below 20 pg/mL) may worsen insulin sensitivity and bone health, partially negating the metabolic benefit of testosterone. [17]

Special Populations

Older Men (65+)

The T-Trials enrolled men aged 65 and older. Testosterone therapy increased 6-minute walk distance by a mean of 10.5 m vs. Placebo (P = 0.03 for physical function) and reduced fat mass significantly, though the Physical Function Trial did not meet its primary endpoint of a 50 m improvement in 6-minute walk. [4] Metabolic benefits in this age group are real but modest.

Men With Obesity

Adipose tissue aromatase activity is elevated in obese men, converting a larger fraction of administered testosterone to estradiol and blunting peak testosterone levels. Men with BMI above 35 kg/m2 may require 150 to 200 mg weekly rather than the standard 100 mg weekly to achieve mid-normal trough levels. Weight loss through caloric restriction or GLP-1 receptor agonist therapy before or alongside TRT reduces aromatase burden and improves the testosterone-to-estradiol ratio. [22]

Men With Type 2 Diabetes

See TIMES2 data above. Glucose monitoring every 2 weeks for the first 3 months is a reasonable precaution given the insulin-sensitizing effect. The net metabolic benefit (lower HbA1c, reduced fat mass) generally outweighs risks in confirmed hypogonadal men with stable diabetes. [16]